Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

Astra Therapeutics has announced today announced that it will present quality of life results from the Phase 1b/2 trial of navenibart (STAR-0215) in a poster displayed at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Scientific Session in Waimea, Hawaii from Sunday, 9 February through Thursday 13 February 2025.

Dr Marc A Riedl, Professor of Medicine and Clinical Director of the US HAEA Angioedema Center at the University of California, San Diego, will present quality of life data from the ALPHA-STAR trial of navenibart in an encore presentation of a poster titled: “Navenibart (STAR-0215) Induces Rapid Improvements of Quality of Life in HAE Patients in the ALPHA-STAR Trial.”

The poster will be exhibited from 3:00pm ET on 9 February until the event’s conclusion on the evening of 13 February 2025.

(Source: Astria)